12:38 ET - AbbVie's 5.2% dividend increase extends the biopharmaceutical company's status as a royal dividend payer. The boost maintains AbbVie's spot in the S&P 500 Dividend Aristocrats Index, whose 69 members have paid a higher dividend for at least 25 straight years. It also keeps AbbVie's place on the smaller list of 60 dividend kings--those that have raised their dividends annually for at least 50 years in a row. While AbbVie's only been around since 2013, it inherited its dividend-paying status from former parent Abbott Labs, another royal payer.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.